InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: hschlauch post# 40451

Friday, 10/20/2017 12:59:32 PM

Friday, October 20, 2017 12:59:32 PM

Post# of 48316
I totally agree that Oncosec and Merck will later develop the combination therapy as a 1st line therapy but the quickest commercial opportunity right now is accelerated approval for checkpoint therapy failure population. I think it is an excellent strategy because success with the PISCES trial would be absolute proof of Oncosec's platform in combination with Keytruda....and shave years of waiting for an approval for validation. Once we get an FDA accelerated approval next year Merck will be all in and expand the pipeline with new trials for TNBC, NSCLC, Head and Neck cancer....etc. The future looks bright.....I gotta wear shades.